SequelSEC

Shattuck Labs, Inc. STTK

Pharmaceutical Preparations · CIK 0001680367 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.00M
Fiscal year ended 2025-12-31
Operating income
-$51.51M
Fiscal year ended 2025-12-31
Free cash flow
-$39.95M
Fiscal year ended 2025-12-31

Shattuck Labs, Inc. (STTK) reported revenue of $1.00M and net income of -$48.81M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Shattuck Labs, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Shattuck Labs, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$1.00M$5.72M$1.66M$652.00K$30.02M$9.93M$9.89M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$51.51M-$80.57M-$91.96M-$103.33M-$45.27M-$36.93M-$25.07M
Net income-$48.81M-$75.41M-$87.30M-$101.94M-$44.97M-$36.60M-$23.98M
Research & development$35.27M$67.21M$74.31M$82.90M$56.56M$37.48M$29.22M
Weighted-average diluted sharesshares 69.58Mshares 50.76Mshares 42.60Mshares 42.38Mshares 42.03Mshares 15.51MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0
Diluted EPS$-0.70$-1.49$-2.05$-2.41$-1.07$-2.36Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$17.24M$19.08M$19.30M$21.08M$18.72M$9.38M$5.74M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Shattuck Labs, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$54.19M$57.39M$125.63M$47.38M$92.27M$157.90M$7.01M
Total assets$91.03M$91.05M$159.56M$205.32M$298.58M$348.99M$44.97M
Current assets$82.48M$79.22M$143.22M$184.58M$288.27M$345.64M$42.44M
Total liabilities$8.64M$11.42M$14.86M$29.17M$26.80M$39.13M$30.45M
Current liabilities$7.05M$8.92M$11.45M$24.96M$24.59M$16.83M$19.98M
Total equity incl. NCI$82.39M$79.63M$144.70M$176.16M$271.79M$309.86M-$34.55M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.10M$2.42M$1.59M$7.17M$10.01M$1.75M$3.05M

Cash flow

Shattuck Labs, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$39.88M-$60.52M-$81.23M-$94.50M-$57.12M-$33.66M-$20.98M
Capital expenditures$71.00K$59.00K$407.00K$11.61M$7.93M$727.00K$470.00K
Investing cash flow-$7.89M-$8.51M$110.86M$49.44M-$10.44M-$146.32M-$3.59M
Financing cash flow$44.57M$787.00K$48.62M$171.00K$1.93M$330.87M-$64.00K
Net change in cash-$3.20M-$68.24M$78.25M-$44.89M-$65.63M$150.88M-$24.63M
Stock-based compensation$7.00M$9.55M$6.94M$6.46M$5.47M$1.27M$461.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$3.70M$3.80M$4.00M$3.10M$1.40M$600.00K$500.00K

Derived

Shattuck Labs, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$39.95M-$60.57M-$81.64M-$106.11M-$65.04M-$34.39M-$21.44M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-5150.8%-1408.3%-5549.6%-15848.0%-150.8%-371.8%-253.5%
FCF margin-3995.3%-1058.8%-4926.7%-16274.8%-216.7%-346.1%-216.9%
SBC / revenue699.5%166.9%418.8%991.1%18.2%12.7%4.7%
Current ratio11.70x8.88x12.51x7.39x11.72x20.53x2.12x
Revenue YoY growth-82.5%245.3%154.1%-97.8%202.2%0.5%Unavailable
Net margin-4880.9%-1318.1%-5268.4%-15635.7%-149.8%-368.5%-242.6%
R&D / revenue3527.3%1174.8%4484.6%12714.6%188.4%377.3%295.5%
CapEx / revenue7.1%1.0%24.6%1781.3%26.4%7.3%4.8%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open STTK in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2019-12-31

Difference 49064000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.